Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. FDA is continuing with its review of the regulatory application for use of BYETTA (exenatide) injection as stand-alone therapy in people with type 2 diabetes who are not achieving acceptable blood sugar control. It is likely that this review will not be complete by the end of 2008, and may extend into 2009.
The details can be read here.
No comments:
Post a Comment